Researcher: DC Page 1 3/27/23
OLR Bill Analysis
sHB 6697
AN ACT CONCERNING THE DEPARTMENT OF CONSUMER
PROTECTION'S RECOMMENDATIONS REGARDING CANNABIS
REGULATION.
TABLE OF CONTENTS:
SUMMARY
§§ 1 & 22-23 — HIGH-TETRAHYDROCANNABINOL (THC) HEMP
PRODUCT
Establishes the category of “high-THC hemp product” and classifies it as marijuana or
cannabis, thus subjecting it to various licensing and regulatory requirements; requires
DESPP to conduct trainings for local police on investigation and enforcement standards
for cannabis and high-THC hemp products
§§ 1, 21, 37 & 39 — CANNABIS-TYPE SUBSTANCES
Replaces references to “cannabis-type substances” with “cannabis” or “marijuana,” thus
consolidating conflicting definitions of the former term
§§ 1-2, 4-9, 15-17 & 46 — CANNABIS TESTING LABORATORY
Differentiates between laboratories for controlled substances and hemp from those for
cannabis and establishes statutory license fees for these laboratories; requires DCP to
adopt regulations for them to test marijuana samples from certain individuals
§ 3 — MEDICAL MARIJUANA PATIENT CAREGIVERS
Expands who may serve as a caregiver for a medical marijuana patient by allowing people
with certain controlled substances convictions to serve and allowing caregivers with a
grandparent or spousal relationship to care for more than one qualifying patient at a time
§§ 9 & 46 — KEY EMPLOYEES
Updates the scope of duties of a cannabis establishment’s financial manager; limits
criminal history checks to key employees, managers, and owners of a cannabis
establishment or cannabis laboratory
§ 10 — DCP APPLICATION
Allows DCP to accept dispensary facility and producer applications after the Social
Equity Council identifies certain criteria; generally prohibits those with access to cannabis
establishment applications and related materials from disclosing certain information,
subject to certain exceptions
§ 11 — SOCIAL EQUITY LOTTERY
Allows social equity applicants to remove backers subject to Social Equity Council
approval and makes minor changes to provisions on lottery rankings and application
completeness 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 2 3/27/23
§§ 12-13, 18 & 19 — EQUITY JOINT VENTURES
Prohibits equity joint ventures that are retailers or hybrid retailers that share certain
common owners from being located within 20 miles from one another; specifies that equity
joint ventures created by converting dispensary facilities are not subject to the lottery
§ 20 — ADVERTISEMENTS
Allows certain professional services to advertise cannabis or cannabis-related services;
expands the billboard prohibition of advertising between certain hours to all billboards;
and exempts certain outdoor business signs from the prohibition on advertising near
certain buildings
§ 23 — MANUFACTURER HEMP
Requires manufacturer hemp to be tested in accordance with the laboratory testing
standards; allows manufacturers to have a sample retested; allows the DCP commissioner
to summarily suspend credentials for certain unauthorized sales; requires certain
warnings and disclosures on manufacturer hemp; makes it a CUTPA violation to violate
certain manufacturer hemp provisions
SUMMARY
This bill makes various changes to the laws around adult-use
cannabis, hemp, and medical marijuana. Among other things, it:
1. establishes a “high-THC hemp product” and classifies it as
marijuana or cannabis, thus subjecting it to the various licensing
and regulatory requirements (e.g., must be sold only by licensed
establishments, tested, and sold only to those age 21 or older
except under the medical marijuana program);
2. differentiates between laboratories for controlled substances and
hemp from those for cannabis (i.e., marijuana);
3. expands who may serve as a medical marijuana caregiver by
allowing those with certain controlled substances convictions to
serve and allowing those with a grandparent or spousal
relationship with a patient to care for more than one qualifying
patient at a time;
4. makes various changes to the adult-cannabis application, lottery,
and equity joint venture provisions, such as specifying the
confidentiality and permissible disclosures of application
materials; 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 3 3/27/23
5. allows certain professional services to advertise cannabis or
cannabis-related services and expands the billboard advertising
prohibition between certain hours to all billboards, not just
electronic or illuminated ones;
6. requires manufacturer hemp to have certain warnings and
disclosures on the packaging and allows manufactuer hemp that
fails a laboratory test to be retested before disposal; and
7. makes numerous minor, technical, and conforming changes.
EFFECTIVE DATE: October 1, 2023, except the provisions on
caregivers, Department of Consumer Protection (DCP) applications and
the Social Equity lottery, and equity joint ventures are effective upon
passage.
§§ 1 & 22-23 — HIGH-TETRAHYDROCANNABINOL (THC) HEMP
PRODUCT
Establishes the category of “high-THC hemp product” and classifies it as marijuana or
cannabis, thus subjecting it to various licensing and regulatory requirements; requires
DESPP to conduct trainings for local police on investigation and enforcement standards
for cannabis and high-THC hemp products
The bill establishes the category of “high-THC hemp product” and
classifies it as marijuana or cannabis, thus subjecting it to various
licensing and regulatory requirements (e.g., must be sold only by
licensed establishments, tested, and sold only to those age 21 or older
except under the medical marijuana program).
Under the bill, a “high-THC hemp product” is a manufacturer hemp
product that has a THC concentration or serving size limit, or is
advertised, labeled, or offered for sale as having such a limit, that
exceeds the following:
1. for a hemp edible, topical, or transdermal patch: (a) one
milligram on a per-serving basis or (b) five milligrams on a per-
container basis;
2. for a hemp tincture, including oil intended for ingestion by
swallowing or sublingual absorption: (a) one milligram on a per- 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 4 3/27/23
serving basis or (b) 25 milligrams on a per-container basis;
3. for a hemp concentrate or extract, including a vape oil, wax, or
shatter: 25 milligrams on a per-container basis; or
4. for a manufacturer hemp product not described above: (a) one
milligram on a per-serving basis, (b) five milligrams on a per-
container basis, or (c) 0.3% on a dry-weight basis.
The bill also modifies the marijuana and cannabis definitions to
replace hemp products that exceed 0.3% total THC concentration on a
dry-weight basis with high-THC hemp products. Correspondingly, the
bill removes the current exemption stating that marijuana does not
include manufacturer hemp products.
Police Training
The bill requires, by December 31, 2023, and annually after that, the
Department of Emergency Services and Public Protection (DESPP), in
conjunction with DCP, to conduct training sessions for local law
enforcement agencies and officers, and publish a training bulletin,
informing them of the investigation and enforcement standards
concerning cannabis and high-THC hemp products.
§§ 1, 21, 37 & 39 — CANNABIS-TYPE SUBSTANCES
Replaces references to “cannabis-type substances” with “cannabis” or “marijuana,” thus
consolidating conflicting definitions of the former term
Current law provides two somewhat different definitions of
“cannabis-type substance,” one in the primary controlled substances
statutes and another in the Responsible and Equitable Regulation of
Adult-Use Cannabis Act (RERACA). In RERACA, the term is the same
as the “cannabis” and “marijuana” definitions.
The bill eliminates references to “cannabis-type substances” and
substitutes it with either “cannabis” or “marijuana,” thus applying
RERACA’s definition to a broader range of statutes, such as the illegal
manufacture or sale of one kilogram or more of marijuana (§ 37). By
doing so, the bill specifies that, as with other laws on marijuana or
cannabis, the terms do not include (1) any substance the federal Food 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 5 3/27/23
and Drug Administration (FDA) approves as a drug and that is
reclassified in any controlled substance schedule, or that the federal
Drug Enforcement Administration unschedules and (2) synthetic
cannabinoids that the DCP commissioner designates as controlled
substances and classifies in the appropriate schedule through
regulations.
§§ 1-2, 4-9, 15-17 & 46 — CANNABIS TESTING LABORATORY
Differentiates between laboratories for controlled substances and hemp from those for
cannabis and establishes statutory license fees for these laboratories; requires DCP to
adopt regulations for them to test marijuana samples from certain individuals
The bill differentiates between laboratories for controlled substances
and hemp from those for cannabis (i.e., marijuana) by renaming the
latter as “cannabis testing laboratories.” It makes corresponding
changes for laboratory employees to rename them as cannabis testing
laboratory employees. The bill also makes various minor, technical, and
conforming changes to effectuate these new names.
The bill specifies that a cannabis testing laboratory may be owned by
an individual, any legal entity, any other person acting in a fiduciary or
representative capacity (whether court appointed or otherwise), or any
combination of these.
License Fees
The bill also establishes a provisional license for a cannabis testing
laboratory, which has a $500 fee and a final license and renewal fee of
$1,000. Under current regulations, a medical marijuana laboratory has a
license and renewal fee of $200 (Conn. Agencies Regs., § 21a-408-29).
Regulations
Existing law requires the DCP commissioner to adopt regulations on
certain laboratory standards. The bill also requires her to adopt
regulations setting procedures for cannabis testing laboratories to
accept marijuana samples from caregivers, qualifying patients, and
consumers (i.e., someone at least age 21) for testing.
Correspondingly, the bill allows a cannabis testing laboratory or
employee to acquire marijuana from these people provided the sample 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 6 3/27/23
is acquired under the regulations.
§ 3 — MEDICAL MARIJUANA PATIENT CAREGIVE RS
Expands who may serve as a caregiver for a medical marijuana patient by allowing people
with certain controlled substances convictions to serve and allowing caregivers with a
grandparent or spousal relationship to care for more than one qualifying patient at a time
The bill expands who may serve as a caregiver for a medical
marijuana qualifying patient by allowing those who have been
convicted of a violation of any law related to the illegal manufacture,
sale, or distribution of controlled substances to serve in this role. Current
law prohibits them from serving.
The bill also allows caregivers with a grandparent or spousal
relationship with the patient to care for more than one qualifying patient
at a time. Existing law already allows those with a parental,
guardianship, conservatorship, or sibling relationship to do so. By law,
a caregiver is someone at least age 18, other than the patient or the
patient’s health care professional (e.g., physician), who is responsible for
managing the patient’s well-being with respect to medical marijuana
use (CGS § 21a-408).
§§ 9 & 46 — KEY EMPLOYEES
Updates the scope of duties of a cannabis establishment’s financial manager; limits
criminal history checks to key employees, managers, and owners of a cannabis
establishment or cannabis laboratory
Financial Manager
Under current law, a cannabis establishment’s financial manager is a
key employee who is generally responsible for overseeing a cannabis
establishment’s financial operations, including various tasks (e.g.,
revenue generation). The bill redefines the scope of the manager’s duty
by specifying that the financial operations under this person’s oversight
include one or more of the following: (1) revenue and expense
management; (2) distributions; (3) tax compliance; (4) budget
development; or (5) budget management and implementation. Current
law specifies a generally similar, but non-exclusive, list of financial
operations (e.g., current law includes revenue generation rather than
revenue and expense management). 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 7 3/27/23
By law, key employees must be at least age 21 and have a DCP license.
Criminal Background Check
Under current law, the DCP commissioner must generally require all
individuals listed on an application for a cannabis establishment license,
laboratory or research program license, or key employee license to
submit to fingerprint-based state and national criminal history checks
before issuing the initial license. The bill limits this background check
requirement to key employees, managers, and owners of applicants for
a cannabis establishment or cannabis testing laboratory license. Similar
to current law, it allows the commissioner to require background checks
for renewal applications.
By law, DCP must charge the applicant a fee equal to the amount the
department is charged to do these checks.
Under the bill, an “owner” is an individual with more than 5%
ownership interest in an applicant. A “manager” is an individual who
is not a key employee and has an ownership interest in, and executive
control of, an applicant. “Executive managerial control” is the authority
or power to direct or influence the applicant’s direction or operation
through agreement, board membership, contract, or voting power.
Under the bill, a key employee, manager, or owner must be denied a
license if the key employee’s background check reveals a disqualifying
conviction. By law, a disqualifying conviction is a conviction in the last
10 years of certain offenses (e.g., certain fraud-related crimes).
By law, the commissioner is allowed to accept a third-party local and
national criminal background check submitted by an applicant for a
backer or key employee license or renewal instead of a fingerprint-based
national criminal history records check. A “backer” is an individual
with a direct or indirect financial interest in a cannabis establishment.
§ 10 — DCP APPLICATION
Allows DCP to accept dispensary facility and producer applications after the Social
Equity Council identifies certain criteria; generally prohibits those with access to cannabis
establishment applications and related materials from disclosing certain information,
subject to certain exceptions 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 8 3/27/23
Dispensary Facility and Producer Applications
Current law allows DCP to accept applications for certain cannabis
licenses within 30 days after the Social Equity Council identifies the
criteria for social equity applicants. The bill expands the list of allowable
applications to include dispensary facilities and producers. As under
existing law, applicants must indicate whether they want to be
considered for treatment as a social equity applicant.
Application Information Disclosure
The bill generally prohibits current or former state officers or
employees, or employees of anyone who had access to a submitted
application, to disclose the application or any information included in
or submitted with it.
Under the bill, the commissioner may disclose the following
information about a submitted application:
1. the applicant’s name, address, and social equity designation, if
any;
2. the license type for which the application was submitted;
3. the applicant owner’s name, e-mail address, and telephone
number;
4. the ownership interest that an owner of a social equity applicant
holds in the applicant, expressed as a percentage of all ownership
interests in the applicant;
5. the name and address of the person serving as the applicant’s
primary business contact;
6. the application number assigned to the application;
7. the date the application was submitted to DCP;
8. information on the applicant’s formation, including the
applicant’s business entity type, formation date and place, and
business registration number as it appears on the Secretary of the 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 9 3/27/23
State’s electronic business portal; and
9. the name of all cannabis businesses associated with the applicant
and listed on the application.
In addition to the information described above, the commissioner
may, in her sole discretion, disclose any personal information or
financial document associated with a submitted application to:
1. a federal, state, or local government agency acting in the course
of its governmental functions, or a person acting on behalf of the
agency in performing these functions;
2. a college or university conducting research or assisting the state
in reviewing the applications, if the college or university agrees
not to disclose any personally identifying information or
confidential business information and deidentifies any personal
or financial information it receives from DCP before releasing
any related report, study, survey, or similar document;
3. a court officer in connection with an administrative, arbitration,
civil, or criminal proceeding in a court or before a government
agency or self-regulatory body, including serving process,
performing an investigation in anticipation of litigation, an order
or the execution or enforcement of a court judgment or order,
provided the person given the information or document is a
party in interest to the proceeding;
4. a state marshal while performing his or her duties; or
5. the applicant or the applicant’s owner to confirm the accuracy of
any information or document the applicant or owner submitted
to DCP in connection with the application.
Under the bill, any personal information or financial document the
commissioner discloses must remain confidential. In addition, the bill
prohibits anyone receiving this information or documentation from the
commissioner from further distributing it in a way that allows another
person to identify any person referenced in, and related to, the 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 10 3/27/23
information or document, unless this disclosure is required under other
applicable law.
§ 11 — SOCIAL EQUITY LOTTERY
Allows social equity applicants to remove backers subject to Social Equity Council
approval and makes minor changes to provisions on lottery rankings and application
completeness
Rankings
The bill eliminates a duplicative requirement that the third-party
lottery operator rank applications numerically from one to the
maximum number DCP sets. As under existing law, the operator must
still rank all applications numerically in the order they were drawn,
including those that exceed the number to be considered.
Application Completeness
By law, DCP must review each application to be considered, as the
third-party operator or council identifies, to confirm it is complete. For
these purposes, the bill deems an application complete if each backer of
the applicant completes the backer’s background check submission
within 30 days after DCP sends notice disclosing that the department
has selected the applicant for review.
Determination of Ownership Cap
In addition to determining completeness, current law requires the
council to determine whether any application includes a backer that
would result in a common ownership violation of having two or more
licenses in the same license type or category. The bill expands this
determination to include whether the lottery applicant has two or more
licenses or includes a backer with managerial control over two such
licenses. By law, the following are considered to be the same license
category: (1) a dispensary facility, retailer, and hybrid retailer license
and (2) producer, cultivator, and micro-cultivator license.
Backer Removal
Under current law, an applicant can remove a backer before the
application is submitted for a final license, unless the removal would
result in a social equity applicant no longer qualifying as a social equity 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 11 3/27/23
applicant. The bill allows (1) social equity applicant removals as long as
any change to a social equity applicant is reviewed and approved by the
Social Equity Council before being reviewed by DCP and (2) backers to
be removed from a cannabis establishment application selected through
the general lottery at any time with notice to DCP.
§§ 12-13, 18 & 19 — EQUITY JOINT VENTURE S
Prohibits equity joint ventures that are retailers or hybrid retailers that share certain
common owners from being located within 20 miles from one another; specifies that equity
joint ventures created by converting dispensary facilities are not subject to the lottery
Location Limitation
Current law prohibits equity joint ventures that share a common
producer or backer or dispensary facility or backer or owner from being
located within 20 miles of another commonly owned equity joint
venture.
The bill instead prohibits equity joint ventures that are retailers or
hybrid retailers from being located within 20 miles of each other if they
share a (1) common cultivator or backer, (2) dispensary facility or owner,
or (3) hybrid retailer or owner. Existing law already prohibits this for
equity joint ventures with a common producer or backer.
Lottery Exemption
Under existing law, upon the Social Equity Council’s written
approval, equity joint venture applications created by a
disproportionately impacted area cultivator or producer expanding its
license are not subject to the lottery (CGS §§ 21a-420j & -420m). The bill
specifies that this exemption also applies to dispensary facilities
converting to hybrid retailers who create an equity joint venture.
§ 20 — ADVERTISEMENT S
Allows certain professional services to advertise cannabis or cannabis-related services;
expands the billboard prohibition of advertising between certain hours to all billboards;
and exempts certain outdoor business signs from the prohibition on advertising near
certain buildings
Professional Services
Current law allows only cannabis establishments to advertise any
cannabis or cannabis-related services in Connecticut. The bill also allows 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 12 3/27/23
a person who provides professional services related to cannabis
purchases, sales, or use to advertise cannabis or cannabis-related
services.
Billboards
Current law prohibits advertising by means of an electronic or
illuminated billboard between the hours of 6:00 a.m. and 11:00 p.m. The
bill expands this prohibition to include all billboards, not just electronic
or illuminated ones.
Outdoor Sign Exemption
Current law exempts certain outdoor business signs posted at a
cannabis establishment from the law’s (1) required warning against
underage use and (2) audience requirement (i.e., ascertaining that at
least 90% of the audience is expected to be at least age 21). The bill
additionally exempts these signs from the law’s prohibition on
advertising cannabis or cannabis products or paraphernalia in any
physical form visible to the public within 500 feet from certain buildings
(i.e., elementary or secondary school grounds, recreation centers or
facilities, child care centers, playgrounds, public parks, and libraries).
§ 23 — MANUFACTURER HEMP
Requires manufacturer hemp to be tested in accordance with the laboratory testing
standards; allows manufacturers to have a sample retested; allows the DCP commissioner
to summarily suspend credentials for certain unauthorized sales; requires certain
warnings and disclosures on manufacturer hemp; makes it a CUTPA violation to violate
certain manufacturer hemp provisions
Laboratory Standards
By law, manufacturer hemp must be tested by an independent testing
laboratory in Connecticut. Current law requires that the laboratory test
each sample for microbiological contaminants, mycotoxins, heavy
metals, and pesticide chemical residue, and for purposes of conducting
an active ingredient analysis, if applicable, as determined by the DCP
commissioner. The bill instead requires the samples to be tested
according to the laboratory testing standards set in the policies,
procedures, and regulations the commissioner adopts.
By law, the DCP commissioner must adopt regulations, policies, and 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 13 3/27/23
procedures on various cannabis issues, including laboratory standards
(CGS § 21a-421j).
Retesting
Currently, if a tested sample fails certain tests the manufacturer must
dispose of the entire batch from which it was taken. The bill instead
allows manufacturers to have the sample retested and reanalyzed and,
if the results are satisfactory, use the hemp batch for manufacturing,
processing, and sale.
Under the bill, if a sample does not pass the microbiological,
mycotoxin, heavy metal, or pesticide chemical test the manufacturer
licensee, if it chooses not to dispose of the batch at this stage, must (1)
retest and reanalyze the hemp from which the sample was taken or (2)
remediate the batch through a DCP-approved remediation plan
sufficient to ensure public health and safety. For retesting, the
manufacturer must:
1. have an employee from the same laboratory randomly select
another sample from the same hemp batch; and
2. if the sample used to retest or reanalyze the hemp yields
satisfactory results for all required testing, an employee from a
different laboratory must randomly select a different sample
from the same hemp batch for testing. If both samples yield
satisfactory results for all required testing the hemp batch from
which the samples were taken must be released for
manufacturing, processing, and sale.
For remediation plans, the manufacturer can have any laboratory test
the remediated sample and then a different laboratory perform the final
testing under substantially similar procedures as retesting.
Under the bill, if the manufacturer does not retest, remediate, or pass
subsequent laboratory testing then, as under current law, it must
dispose of the entire batch from which the sample was taken following
DCP-established procedures. 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 14 3/27/23
Advertising Restrictions
Current law prohibits any claim of health impacts, medical effects, or
physical or mental benefits on any advertising for, labeling of, or
marketing of manufacturer hemp products. The bill specifies this
applies regardless of whether the products were manufactured in
Connecticut or elsewhere. By law, a violation is deemed a violation of
the Connecticut Unfair Trade Practices Act (CUTPA).
By law, CUTPA prohibits businesses from engaging in unfair and
deceptive acts or practices. It allows the DCP commissioner to issue
regulations defining an unfair trade practice, investigate complaints,
issue cease and desist orders, order restitution in cases involving less
than $10,000, enter into consent agreements, ask the attorney general to
seek injunctive relief, and accept voluntary statements of compliance. It
also allows individuals to sue. Courts may issue restraining orders;
award actual and punitive damages, costs, and reasonable attorney’s
fees; and impose civil penalties of up to $5,000 for willful violations and
up to $25,000 for a restraining order violation.
Suspension
By law, manufacturer hemp product sellers do not need to be licensed
if they only engage in the following activities:
1. retail or wholesale sale of manufacturer hemp products that
require no further hemp manufacturing and that are obtained
from someone authorized by law in Connecticut or another
jurisdiction to manufacture hemp;
2. acquire manufacturer hemp products only for resale; or
3. retail sale of manufacturer hemp products that are authorized
under federal or state law.
The bill allows the DCP or Department of Revenue Services
commissioner to summarily suspend any credential their respective
department issues to anyone selling manufacturer hemp products in
violation of the provision above. The suspension must be done in
accordance with the Uniform Administrative Procedure Act’s 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 15 3/27/23
procedures for licensing matters.
The bill also makes a violation of this provision and those below a
CUTPA violation.
Synthetic Cannabinoids
The bill prohibits manufacturer hemp products containing synthetic
cannabinoids from being offered for sale in Connecticut or to a
Connecticut consumer.
Packaging and Labeling
Under the bill, no manufacturer hemp product offered for sale in
Connecticut or to a Connecticut consumer, may be packaged, presented,
or advertised in a way that is likely to mislead a consumer by
incorporating any statement, brand, design, representation, picture,
illustration, or other depiction that:
1. bears a reasonable resemblance to trademarked or characteristic
packaging of (a) cannabis offered for sale by a licensed
Connecticut cannabis establishment or on tribal land by a tribal
credentialed cannabis entity, or (b) a commercially available
product other than a cannabis product; or
2. implies that the product (a) is a cannabis product, (b) contains a
total THC concentration greater than 0.3% on a dry-weight basis,
or (c) is a high-THC hemp product.
Food or Other Product for Human Ingestion. The bill prohibits
manufactured hemp products that are a food, beverage, oil, or other
product intended for human ingestion to be distributed or sold in
Connecticut unless the package or package label contains the following:
1. a scannable barcode, website address, or quick response code
that is linked to the certificate of analysis of the final form product
batch by an independent testing laboratory and discloses certain
information about the product (see below);
2. the product’s expiration or best by date, if applicable; 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 16 3/27/23
3. a clear and conspicuous statement disclosing certain warnings
(see below); and
4. if the product is intended to be inhaled, a clear and conspicuous
warning that smoking or vaporizing is hazardous to human
health.
The electronic notice must disclose the:
1. product’s name;
2. product’s manufacturer, packer, or distributor’s name, address,
and telephone number;
3. batch number, which must match the batch number on the
package or label; and
4. concentration of cannabinoids in the product, including total
THC and any marketed cannabinoids or ingredients, which DCP
must establish in policies and procedures or regulations.
The warnings must be that:
1. children or those who are pregnant or breastfeeding should
avoid using the product before consulting with a health care
professional about the product’s safety;
2. products containing cannabinoids should be kept out of reach of
children; and
3. the FDA has not evaluated the product for safety or efficacy.
Cosmetics. The bill prohibits manufactured hemp products that are
topical, soap, or cosmetic from being distributed or sold in Connecticut
unless the product has within the package or on a label affixed to the
package:
1. a substantially similar electronic notice as required for food (see
above); 2023HB-06697-R000226-BA.DOCX
Researcher: DC Page 17 3/27/23
2. the product’s expiration or best by date, if applicable; and
3. the following statement: “THE FDA HAS NOT EVALUATED
THIS PRODUCT FOR SAFETY OR EFFICACY.”.
COMMITTEE ACTION
General Law Committee
Joint Favorable Substitute
Yea 21 Nay 1 (03/07/2023)